UA94719C2 - Применение производного имидазол-2-карбоновой кислоты для лечения или профилактики гематологической злокачественной опухоли - Google Patents

Применение производного имидазол-2-карбоновой кислоты для лечения или профилактики гематологической злокачественной опухоли

Info

Publication number
UA94719C2
UA94719C2 UAA200804647A UAA200804647A UA94719C2 UA 94719 C2 UA94719 C2 UA 94719C2 UA A200804647 A UAA200804647 A UA A200804647A UA A200804647 A UAA200804647 A UA A200804647A UA 94719 C2 UA94719 C2 UA 94719C2
Authority
UA
Ukraine
Prior art keywords
imidazole
prevention
treatment
carboxylic acid
acid derivative
Prior art date
Application number
UAA200804647A
Other languages
English (en)
Ukrainian (uk)
Inventor
Шелли К. Баллентайн
Кристиан Эндрю Бауманн
Джиншенг Чен
Карл Р. Иллиг
Санат К. Мегалла
М. Джонатан Рудольф
Роберт У. Туман
Марк Дж. Уолл
Кеннет Уилсон
Дана Л. Джонсон
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of UA94719C2 publication Critical patent/UA94719C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Abstract

Данное изобретение касается применения соединения формулы:или его сольвата, гидрата, таутомера или фармацевтически приемлемой соли для лечения или профилактики гематологической злокачественной опухоли.
UAA200804647A 2005-10-18 2006-10-17 Применение производного имидазол-2-карбоновой кислоты для лечения или профилактики гематологической злокачественной опухоли UA94719C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72768705P 2005-10-18 2005-10-18

Publications (1)

Publication Number Publication Date
UA94719C2 true UA94719C2 (ru) 2011-06-10

Family

ID=37864477

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200804647A UA94719C2 (ru) 2005-10-18 2006-10-17 Применение производного имидазол-2-карбоновой кислоты для лечения или профилактики гематологической злокачественной опухоли

Country Status (19)

Country Link
US (1) US7795279B2 (ru)
EP (1) EP1951234A2 (ru)
JP (2) JP2009511628A (ru)
KR (1) KR101443651B1 (ru)
CN (1) CN101340909B (ru)
AU (1) AU2006304897B2 (ru)
BR (1) BRPI0617489A2 (ru)
CA (1) CA2626623C (ru)
CR (1) CR9984A (ru)
EA (1) EA200801118A1 (ru)
EC (1) ECSP088387A (ru)
GT (1) GT200800042A (ru)
IL (1) IL190727A (ru)
NO (1) NO20082223L (ru)
NZ (1) NZ595182A (ru)
SV (1) SV2008002880A (ru)
UA (1) UA94719C2 (ru)
WO (1) WO2007048088A2 (ru)
ZA (1) ZA200804253B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846630B2 (en) * 1996-10-18 2005-01-25 Takara Shuzo Co., Ltd. Nucleic acid encoding receptor type protein kinase
PT1807077T (pt) * 2004-10-22 2017-01-06 Janssen Pharmaceutica Nv Inibidores de quinase c-fms
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
CN101340909B (zh) * 2005-10-18 2012-01-11 詹森药业有限公司 抑制flt3激酶的方法
EA014907B1 (ru) * 2006-03-09 2011-02-28 Фармакопейа, Инк. ИНГИБИТОРЫ Mnk2 НА ОСНОВЕ 8-ГЕТЕРОАРИЛПУРИНА ДЛЯ ЛЕЧЕНИЯ МЕТАБОЛИЧЕСКИХ НАРУШЕНИЙ
WO2007124369A2 (en) * 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. Method of inhibiting c kit kinase
PE20080074A1 (es) 2006-04-20 2008-02-11 Janssen Pharmaceutica Nv Derivados de amida como agentes inhibidores de la quinasa c-fms
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
DK2021335T3 (da) 2006-04-20 2011-09-05 Janssen Pharmaceutica Nv Heterocykliske forbindelser som C-FMS-kinasehæmmere
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US9109227B2 (en) 2010-01-05 2015-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
WO2011113041A2 (en) * 2010-03-12 2011-09-15 The Johns Hopkins University Neutralization of flt3 ligand as a leukemia therapy
BR112014007622A2 (pt) 2011-09-30 2017-04-04 Oncodesign Sa inibidores de flt3 cinase macrocíclicos
IN2015DN00659A (ru) 2012-08-07 2015-06-26 Janssen Pharmaceutica Nv
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
CN104370880A (zh) * 2013-01-24 2015-02-25 韩冰 一类蛋白酶抑制剂及其制备方法和用途
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
MX363432B (es) 2013-07-22 2019-03-22 Idorsia Pharmaceuticals Ltd Derivados 1-(piperazin-1-il)-2-([1,2,4]triazol-1-il)-etanona.
WO2016016370A1 (en) 2014-07-31 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
DK3245203T3 (en) 2015-01-15 2019-02-18 Idorsia Pharmaceuticals Ltd HYDROXYALKYL-PIPERAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
EP3559006A4 (en) * 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
US20200171022A1 (en) 2017-05-17 2020-06-04 Inserm (Institut National De La Santé Et Da La Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
WO2018217766A1 (en) 2017-05-22 2018-11-29 Whitehead Institute For Biomedical Research Kcc2 expression enhancing compounds and uses thereof
US11285131B2 (en) 2017-08-04 2022-03-29 Merck Sharp & Dohme Corp. Benzo[b]thiophene STING agonists for cancer treatment
RU2020109328A (ru) 2017-08-04 2021-09-06 Мерк Шарп И Доум Корп. Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2193143T3 (es) 1992-03-05 2003-11-01 Univ Texas Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
ATE269357T1 (de) 1999-04-28 2004-07-15 Univ Texas Zusammensetzungen und verfahren zur krebsbehandlung durch die selektive hemmung von vegf
US6852752B2 (en) * 1999-12-17 2005-02-08 Vicuron Pharmaceuticals Inc. Urea compounds, compositions and methods of use and preparation
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0005357D0 (en) * 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
WO2002032861A2 (en) 2000-10-17 2002-04-25 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
US7101884B2 (en) 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
EP1441737B1 (en) 2001-10-30 2006-08-09 Novartis AG Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
RU2316554C2 (ru) 2001-12-27 2008-02-10 Тереванс, Инк. Производные индолина, используемые как ингибиторы протеинкиназы
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
BR0313397A (pt) 2002-08-14 2005-06-28 Vertex Pharmaceuticals Incorpo Inibidores de proteina cinase e usos destes
WO2004018419A2 (en) 2002-08-23 2004-03-04 Chiron Corporation Benzimidazole quinolinones and uses thereof
JPWO2004039782A1 (ja) 2002-10-29 2006-03-02 麒麟麦酒株式会社 Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
SG148864A1 (en) 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
EP1581526B1 (en) 2002-12-18 2009-03-11 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
US7429603B2 (en) * 2003-04-25 2008-09-30 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
US7427683B2 (en) * 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
US20050113566A1 (en) * 2003-04-25 2005-05-26 Player Mark R. Inhibitors of C-FMS kinase
PT1807077T (pt) * 2004-10-22 2017-01-06 Janssen Pharmaceutica Nv Inibidores de quinase c-fms
US20060281771A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
CN101340909B (zh) * 2005-10-18 2012-01-11 詹森药业有限公司 抑制flt3激酶的方法
KR20080066069A (ko) * 2005-11-03 2008-07-15 버텍스 파마슈티칼스 인코포레이티드 키나제 억제제로서 유용한 아미노피리미딘
EP1951716B1 (en) * 2005-11-16 2011-05-04 Vertex Pharmaceuticals, Inc. Aminopyrimidines useful as kinase inhibitors

Also Published As

Publication number Publication date
JP2014129407A (ja) 2014-07-10
WO2007048088A2 (en) 2007-04-26
US20070149572A1 (en) 2007-06-28
WO2007048088A3 (en) 2007-06-07
SV2008002880A (es) 2010-01-05
NO20082223L (no) 2008-07-02
CA2626623A1 (en) 2007-04-26
CR9984A (es) 2008-09-09
CN101340909A (zh) 2009-01-07
CA2626623C (en) 2016-08-30
US7795279B2 (en) 2010-09-14
BRPI0617489A2 (pt) 2011-07-26
EP1951234A2 (en) 2008-08-06
IL190727A0 (en) 2008-12-29
IL190727A (en) 2015-05-31
CN101340909B (zh) 2012-01-11
ZA200804253B (en) 2009-11-25
AU2006304897B2 (en) 2012-07-12
EA200801118A1 (ru) 2008-10-30
KR20080064867A (ko) 2008-07-09
AU2006304897A1 (en) 2007-04-26
NZ595182A (en) 2012-12-21
ECSP088387A (es) 2008-05-30
GT200800042A (es) 2008-11-03
JP2009511628A (ja) 2009-03-19
KR101443651B1 (ko) 2014-09-23

Similar Documents

Publication Publication Date Title
UA94719C2 (ru) Применение производного имидазол-2-карбоновой кислоты для лечения или профилактики гематологической злокачественной опухоли
SG171592A1 (en) Method of inhibiting c-kit kinase
GEP20125589B (en) TRIAZINE COMPOUNDS AS P13 KINASE AND mTOR INHIBITORS
WO2008147864A3 (en) Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
HK1139863A1 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
MX2009008338A (es) Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.
EP2288260A4 (en) TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD
MX336271B (es) Compuestos de triazolopiridina inhibidores de jak y los metodos.
HK1093159A1 (en) Monocyclic heterocycles as kinase inhibitors
TNSN08088A1 (en) Substituted benzimidazoles as kinase inhibitors
MX2009012719A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
WO2009108383A3 (en) Substituted xanthine derivatives
UA103351C2 (ru) ПРОИЗВОДНЫЕ ТИЕНО[3,2-c]ПИРИДИНА КАК ИНГИБИТОРЫ КИНАЗ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ РАКА
TW200716598A (en) Aminoquinoline and aminoquinazoline kinase modulators
MX2007013624A (es) Inhibidores de proteina cinasa.
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
WO2008076949A3 (en) Quinazoline derivatives and methods of treatment
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors
WO2008128009A3 (en) Aminopyrimidines useful as kinase inhibitors
IN2012DN01642A (ru)
MX2011012522A (es) Inhibidores de pirazol sustituido de proteina cinasa c-met.
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer
WO2012122532A3 (en) Compositions and methods for treatment of hyperuricemia
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors